### Guideline Page and Request

**PROS-9 and -13**

Internal request: In response to the FDA approval of the new fine-particle formulation of abiraterone used in combination with methylprednisolone, the panel should vote on its inclusion as an option for the treatment of men with N1 or M1 castration-naïve prostate cancer.

Based on the data in the noted references, the panel consensus was to include the fine-particle formulation of abiraterone in combination with methylprednisolone as an option for the treatment of men with N1 or M1 castration-naïve prostate cancer. This is a category 2B recommendation.


#### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>7</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

### PROS-15, -16, -17

Internal request: In response to the FDA approval of the new fine-particle formulation of abiraterone used in combination with methylprednisolone for the treatment of men with M1 castration-resistant prostate cancer, the panel should vote on its inclusion as an option for treatment in this setting.

Based on the data in the noted references, the panel consensus was to include the fine-particle formulation of abiraterone in combination with methylprednisolone as an option for the treatment of men with M1 castration-resistant prostate cancer. This is a category 2A recommendation.


#### Institution Vote

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>24</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>